EFFECT OF DIFFERENT STATINS IN ANIMAL MODEL OF ANXIETY IN WISTAR RATS

Authors

  • Jyothsna Vc Department of Pharmacology, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, India.
  • Balaji O Department of Pharmacology, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, India.
  • Bharti Chogtu Department of Pharmacology, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, India.

DOI:

https://doi.org/10.22159/ajpcr.2018.v11i10.24222

Keywords:

Alprazolam, Anxiety, Latency period, Line crossing, Pitavastatin, Rosuvastatin

Abstract

Objective: Pleiotropic mechanisms of statins have been explored in treating neurological disorders such as generalized anxiety disorder and depression. Hence, the aim of the present study is to evaluate the effect of different statins in animal model of anxiety in Wistar rats.

Methods: Sixty rats were divided into five groups of 6 rats each for each model. Two models were used, elevated plus maze and open-field model. Grouping is as follows: Group 1 - normal control (0.9% saline), Group 2 - alprazolam 0.5 mg/kg, Group 3 - atorvastatin 10 mg/kg, Group 4 - rosuvastatin 10 mg/kg, and Group 5 - pitavastatin 10 mg/kg. All drugs were given orally for 30 days.

Results: In open-field model and in elevated plus maze, alprazolam, atorvastatin, rosuvastatin, and pitavastatin in comparison with control showed significant antianxiety effect (p<0.01 and p<0.001), respectively.

Conclusion: Hence, further clinical trials can be done to see the effect of various statins on generalized anxiety disorder in comparison with standard antianxiety drugs.

 

Downloads

Download data is not yet available.

References

Pathak NL, Kasture SB, Bhatt NM, Patel RG. Experimental modeling of anxiety. J Appl Pharm Sci 2011;1:6-10.

Centre for Addiction and Mental Health, Rector NA. Anxiety disorders: An information guide. Centre for Addiction and Mental Health; 2005.

Young AS, Klap R, Sherbourne CD, Wells KB. The quality of care for depressive and anxiety disorders in the United States. Arch Gen Psychiatry 2001;58:55-61.

Golomb BA, Evans MA. Statin adverse effects. Am J Cardiovasc Drugs 2008;8:373-418.

Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005;45:89-118.

Pemminati S, Colaco MB, Patchava D, Shivaprakash G, Ullal, DS, Gopalakrishna HN, et al. Role of statins in animal models of anxiety in normo-cholesterolemic rats. J Pharm Res 2012;5:3764-6.

Sethy VH, Hodges DH. Antidepressant activity of alprazolam in a reserpine-induced model of depression. Drug Dev Res 1985;5:179-84.

Citraro R, Chimirri S, Aiello R, Gallelli L, Trimboli F, Britti D, et al. Protective effects of some statins on epileptogenesis and depressive-like behavior in WAG/Rij rats, a genetic animal model of absence epilepsy. Epilepsia 2014;55:1284-91.

Herbet M, Gawrońska-Grzywacz M, Izdebska M, Piątkowska-Chmiel I, Jagiełło-Wójtowicz E. Impact of combined treatment with rosuvastatin and antidepressants on liver and kidney function in rats. Exp Ther Med 2016;11:1459-64.

Li F, Zhang M, Xu D, Liu C, Zhong ZY, Jia LL, et al. Co-administration of paroxetine and pravastatin causes deregulation of glucose homeostasis in diabetic rats via enhanced paroxetine exposure. Acta Pharm Sinica 2014;35:792-805.

Yanuck D, Mihos CG, Santana O. Mechanisms and clinical evidence of the pleiotropic effects of the hydroxy-methyl-glutaryl CoA reductase inhibitors in central nervous system disorders: A comprehensive review. Int J Neurosci 2012;122:619-29.

Walf AA, Frye CA. The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nat Protocols 2007;2:322-8.

Basso DM, Beattie MS, Bresnahan JC. A sensitive and reliable locomotor rating scale for open field testing in rats. J Neurotrauma 1995;12:1-21.

Drugan RC, Morrow AL, Weizman R, Weizman A, Deutsch SI, Crawley JN, et al. Stress-induced behavioral depression in the rat is associated with a decrease in GABA receptor-mediated chloride ion flux and brain benzodiazepine receptor occupancy. Brain Res 1989;487:45‑51.

Kuczmierczyk AR, Barbee JG, Bologna NA, Townsend MH. Serum cholesterol levels in patients with generalized anxiety disorder (GAD) and with GAD and comorbid major depression. Can J Psychiatry 1996;41:465-8.

Muldoon MF, Barger SD, Ryan CM, Flory JD, Lehoczky JP, Matthews KA, et al. Effects of lovastatin on cognitive function and psychological well-being. Am J Med 2000;108:539.

Harrison RW, Ashton CH. Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers. Br J Clin Pharmacol 1994;37:231-6.

Kumar A, Vashist A, Kumar P, Kalonia H, Mishra J. Protective effect of HMG coA reductase inhibitors against running wheel activity induced fatigue, anxiety like behavior, oxidative stress and mitochondrial dysfunction in mice. Pharmacol Rep 2012;64:1326-36.

Santos T, Baungratz MM, Haskel SP, de Lima DD, da Cruz JN, Magro DD, et al. Behavioral interactions of simvastatin and fluoxetine in tests of anxiety and depression. Neuropsychiatr Dis Treat 2012;8:413-22.

ElBatsh MM. Antidepressant-like effect of simvastatin in diabetic rats. Can J Physiol Pharmacol 2015;93:649-56.

Ludka FK, Zomkowski AD, Cunha MP, Dal-Cim T, Zeni AL, Rodrigues AL, et al. Acute atorvastatin treatment exerts antidepressant-like effect in mice via the L-arginine-nitric oxide-cyclic guanosine monophosphate pathway and increases BDNF levels. Eur Neuropsychopharmacol 2013;23:400-12.

Stafford L, Berk M. The use of statins after a cardiac intervention is associated with reduced risk of subsequent depression: Proof of concept for the inflammatory and oxidative hypotheses of depression? J Clin Psychiatry 2011;72:1229-35.

Huang CI, Lin LC, Tien HC, Que J, Ting WC, Chen PC, et al. Hyperlipidemia and statins use for the risk of new-onset anxiety/depression in patients with head and neck cancer: A population-based study. PLoS One 2017;12:e0174574.

Published

07-10-2018

How to Cite

Vc, J., B. O, and B. Chogtu. “EFFECT OF DIFFERENT STATINS IN ANIMAL MODEL OF ANXIETY IN WISTAR RATS”. Asian Journal of Pharmaceutical and Clinical Research, vol. 11, no. 10, Oct. 2018, pp. 369-71, doi:10.22159/ajpcr.2018.v11i10.24222.

Issue

Section

Original Article(s)